Hutchison China Meditech Limited (Chi-Med) announced that admission to trading on AIM became effective, and dealings in the ordinary shares of the Company started, at 8.00am, 19th May 2006, under the ticker symbol “HCM”.
The ISIN number is KYG4672N1016. Dealings are conducted in CREST through Depository Interests each representing an interest in one ordinary share.
Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine (“TCM”) and botanical ingredients. Chi-Med’s overall aim is to draw on the untapped wealth of knowledge and history of usage in the TCM industry to develop pharmaceutical and consumer products for the global market.
On 10th May 2006, Chi-Med announced that it will have raised gross proceeds of approximately ￡40 million through a placing with institutional and other qualified investors and via a Hong Kong Preferential Offering to qualifying shareholders of Hutchison Whampoa Limited of a total of 14,545,454 new shares at a price of 275 pence per ordinary share (the “Placing Price”). Based on that Placing Price, the market capitalisation of Chi-Med on admission will be approximately ￡141 million.
Lazard & Co., Limited is Nominated Advisor to Chi-Med and Panmure Gordon are Chi-Med’s brokers to the placing.